Evidence map›Paper›PMID 35769838›Full record

ReviewJournal of research in pharmacy practice

Potential Benefits of Selenium Supplementation in Patients with Kidney Disease.

Shirinsadat Badri, Sahar Vahdat, Morteza Pourfarzam, Samaneh Assarzadeh, Shiva Seirafian, Sara Ataei

Abstract readReview
In one paragraph

Review in Journal of research in pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shirinsadat BadriDepartment of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran.
Sahar VahdatIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Morteza PourfarzamDepartment of Clinical Biochemistry, Isfahan University of Medical Sciences, Isfahan, Iran.
Samaneh AssarzadehDepartment of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran.
Shiva SeirafianIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Sara AtaeiDepartment of Clinical Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trace element deficiency is common among patients with end-stage renal disease (ESRD); the reason is that since these patients undergo dialysis, they lose these elements more than healthy people, and also the use of trace elements is restricted due to loss of appetite. Selenium (Se) is a trace element that is essential for the oxidative stress defense system. Se deficiency leads to some complications similar to those often seen in ESRD patients, such as all-cause mortality due to cardiovascular diseases, bone loss, uric acid elevation, and anemia. This article aims to review the evidence on consequences of Se deficiency in ESRD patients, as well as effects of Se supplementation in hemodialysis patients. Multiple databases were searched to summarize the available evidence on selenium's role in kidney diseases. Since the complications of ESRD and those of Se deficiency are mostly similar, this triggers the idea that Se deficiency may be considered as a cause of these problems, but it needs to be more assessed that Se deficiency is a single factor or there are other factors participated in. Also the role of Se supplementation on resolving the mentioned complications, needs to be more studied through welldesigned clinical studies.

Indexed as

Hemodialysiskidney diseaseperitoneal dialysisSelenium supplementation

Identifiers

PMID35769838
PMCPMC9235365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.